Wells Fargo analyst David Maris said the new steps announced by Mylan to enhance access to EpiPen are a "good start," but do not go far enough to address the underlying issues concerning the Senate and many parents. Specifically, Maris noted that it appears that Mylan is not actually reducing the price of EpiPen, just "cost-shifting," and that its plan does nothing to reimburse the parents and children who have already endured very high prices, including those suffered for this back-to-school season. Maris thinks the steps Mylan announced this morning will not satisfy the company's many critics and that an FTC investigation and Senate hearings are still a possibility. The firm keeps a Market Perform rating on Mylan shares, which are up about 2% but off their opening highs.